Testosterone

CHARLOTTESVILLE, VA, UNITED STATES, July 30, 2025 / EINPresswire.com / -- Contraline, Inc. , a clinical-stage biotechnology company developing novel male contraceptives, today announced that it has exercised its option to exclusively license the Nestorone ® /Testosterone (NES/T) gel from the Population Council . NES/T is poised to become the first FDA-approved hormonal contraceptive for men. Developed by the Population Council’s Center for Biomedical Research and the 𝘌𝘶𝘯𝘪𝘤𝘦 𝘒𝘦𝘯𝘯𝘦𝘥𝘺 𝘚𝘩𝘳𝘪𝘷𝘦𝘳 National Institute of Child Health and Human Development (NICHD), NES/T is a once-daily topical gel that delivers Nestorone and testosterone, suppressing sperm production while maintaining normal hormone levels. The first-in-class male contraceptive recently completed a global Phase 2b clinical trial involving 462 couples. NES/T is the most advanced investigational male contraceptive studied to date, with promising potential for high efficacy, safety, reversibility, and patient acceptability. Contraline’s decision to exercise its exclusive option agreement for NES/T marks a major milestone in its mission to transform the landscape of contraception and advance reproductive equality. Contraline is uniquely positioned to advance NES/T through a Phase 3 trial and into commercialization. “This marks a pivotal moment not just for Contraline, but for the future of contraception. With NES/T and ADAM, we will be advancing two male contraceptive programs towards late-stage trials and approvals, positioning us at the forefront of a category that will reshape global reproductive health,” said Kevin Eisenfrats, Co-Founder & CEO of Contraline. “The enthusiasm and demand we have seen from the patients and investigators involved in the NES/T trials have been unmistakable: the world is ready for male birth control. We’re proud to build on the decades of groundbreaking work by the Population Council and NICHD and carry this momentum into Phase 3 and beyond.” “We are delighted that Contraline, a leader in male contraceptive development, has exercised their option to license the NES/T contraceptive gel,” said Anita Garg, Senior Director of Strategy and Commercial Relations at the Population Council’s Center for Biomedical Research. “Contraline has demonstrated their vision and commitment to pioneer contraceptive options for men, and we look forward to them leading the product through the final stages of development and into the hands of users.” Contraline will transition the NES/T program in-house upon execution of the license agreement. With expanded choice for men, Contraline is one step closer to making family planning a shared responsibility. Disclaimer NES/T The NES/T gel is a U.S. FDA-Regulated Investigational Drug Product not yet authorized by the US FDA or any other regulatory authority worldwide. It is available only for investigational use in approved clinical trials. About Contraline, Inc. Contraline, Inc. is a clinical-stage, biotechnology company focused on innovation in reproductive health. The company’s mission is to develop novel male contraceptives that are safe, effective, and reversible. Visit www.contraline.com . About the Population Council The Population Council is a leading research organization dedicated to building an equitable and sustainable world that enhances the health and well-being of current and future generations. We generate ideas, produce evidence, and design solutions to improve the lives of people around the world. Learn more at www.popcouncil.org . Media Contact Martin Sandgren Klover Communications press@klovercommunications.com (949) 438-0425 Kevin Eisenfrats Contraline, Inc. email us here Visit us on social media: LinkedIn Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

The Pros and Cons of Boosting Natural Testosterone Production with Selective Estrogen Receptor Modulators (SERMs) Clomiphene and Enclomiphene represent a revolutionary shift in how we manage low testosterone in men through enhancing the body’s natural hormone production as an alternative to traditional TRT.” — Chris Rue, FNP-C METAIRIE, LA, UNITED STATES, July 30, 2025 / EINPresswire.com / -- Metairie, LA– As the conversation around men’s hormonal health continues to grow, MOPE Clinic and Chris Rue, FNP-C are helping to lead the way in providing evidence-based options for testosterone optimization. One of the most compelling developments in this area is the use of medications like Clomiphene citrate and Enclomiphene citrate to stimulate the body’s own production of testosterone. These compounds, known as Selective Estrogen Receptor Modulators (SERMs), have gained popularity among men looking for an alternative to traditional testosterone replacement therapy (TRT). At MOPE Clinic, patients receive personalized, safe, and medically supervised hormone care tailored to their unique needs. What Are Clomiphene and Enclomiphene? Clomiphene citrate is a well-known fertility medication that has long been used in women. However, in recent years, it has found an important place in men’s health care. Enclomiphene, its purified isomer, has emerged as a more targeted treatment option with fewer estrogenic side effects. Both medications work by blocking estrogen receptors in the hypothalamus. This action tricks the brain into thinking estrogen levels are low, which leads to an increase in gonadotropin-releasing hormone (GnRH). In turn, GnRH stimulates the pituitary gland to produce luteinizing hormone (LH) and follicle-stimulating hormone (FSH). These hormones tell the testes to produce more testosterone and sperm. In other words, Clomiphene and Enclomiphene help reactivate the body’s natural testosterone production—a critical distinction from TRT, which replaces testosterone from external sources and often shuts down the body’s own production. The Benefits of Clomiphene and Enclomiphene At MOPE Clinic, Chris Rue, FNP-C emphasizes a holistic, functional approach to hormone optimization. In that light, Clomiphene and Enclomiphene offer several unique advantages: 1. Preservation of Fertility Unlike TRT, which can suppress sperm production, Clomiphene and Enclomiphene support spermatogenesis. This makes them ideal for younger men or those planning to maintain fertility while improving their testosterone levels. 2. Endogenous Testosterone Production These SERMs stimulate the body’s own production of testosterone. This avoids the testicular shrinkage and hypothalamic-pituitary-testicular axis (HPTA) suppression commonly seen with TRT. 3. Oral Administration Clomiphene and Enclomiphene are taken orally, typically as a pill taken daily or several times per week. This is more convenient than injections, gels, or pellets required in most TRT protocols. 4. Lower Risk of Erythrocytosis TRT can increase red blood cell count, raising the risk of blood clots. Clomiphene and Enclomiphene pose a lower risk for this complication. 5. Fewer Legal and Regulatory Concerns Clomiphene and Enclomiphene are not classified as controlled substances in the United States. This makes prescribing and accessing them more straightforward for both providers and patients. Who Is a Good Candidate? According to Chris Rue, FNP-C, ideal candidates for Clomiphene or Enclomiphene therapy include: Men under age 50 experiencing symptoms of low testosterone (fatigue, low libido, mood changes, etc.) Patients who still want to preserve fertility Individuals hesitant to start long-term TRT Men with secondary hypogonadism, where the problem lies in the brain or pituitary, not the testes At MOPE Clinic, patients undergo comprehensive lab testing, physical exams, and hormone assessments to determine whether Clomiphene or Enclomiphene is an appropriate treatment option. What Are the Limitations? Despite their many benefits, Clomiphene and Enclomiphene are not perfect solutions for every patient. At MOPE Clinic, education and transparency are key. Here are the primary limitations patients should consider: 1. Not Effective for Primary Hypogonadism If the testes are damaged or unresponsive (primary hypogonadism), Clomiphene and Enclomiphene won’t help. These medications require a functioning hypothalamic-pituitary-testicular axis. 2. Estrogenic Side Effects (Clomiphene) Some men experience visual disturbances, mood swings, or gynecomastia (breast tissue development) due to the mixed estrogenic effects of Clomiphene. Enclomiphene, being the purified isomer, generally causes fewer of these issues. 3. Variable Response Not all men respond the same. Some may see only modest increases in testosterone or symptom improvement. Ongoing monitoring is essential. 4. Off-Label Use Currently, neither Clomiphene nor Enclomiphene is FDA-approved specifically for male hypogonadism. However, off-label use is common and backed by numerous clinical studies. 5. Requires Patience and Follow-Up Clomiphene and Enclomiphene require several weeks to months to fully evaluate effectiveness. Frequent follow-up lab testing is necessary to track LH, FSH, estradiol, and testosterone levels. Research and Clinical Evidence Clinical studies have demonstrated the efficacy of Clomiphene citrate in raising testosterone levels in men with secondary hypogonadism. One study published in Fertility and Sterility showed that Clomiphene increased serum testosterone from an average of 247 ng/dL to 610 ng/dL after 3 months of therapy ( https://pubmed.ncbi.nlm.nih.gov/16422830/ } Another study in The Journal of Urology found that Enclomiphene significantly increased testosterone levels while maintaining sperm production—something not typically seen with TRT ( https://pubmed.ncbi.nlm.nih.gov/26496621/ ) MOPE Clinic’s Personalized Approach At MOPE Clinic, Chris Rue, FNP-C ensures that every patient receives a tailored treatment plan that considers hormonal balance, lifestyle, nutrition, and long-term health. Rather than treating labs alone, the clinic focuses on relieving symptoms, restoring well-being, and preserving function. Patients receive ongoing support, education, and adjustments to therapy as needed. Whether you’re struggling with fatigue, weight gain, low libido, or brain fog, MOPE Clinic offers a comprehensive, patient-first approach to hormonal health. Conclusion: A Modern Option for a Modern Man Clomiphene and Enclomiphene represent a revolutionary shift in how we manage low testosterone in men. By enhancing the body’s natural hormone production, these medications provide a compelling alternative to conventional testosterone replacement therapy. Still, they are not without limitations. At MOPE Clinic, men can expect evidence-based guidance, thorough evaluations, and compassionate care that respects their goals—whether that’s reclaiming energy, improving libido, or preserving fertility. Schedule a Consultation Today Men interested in learning whether Clomiphene or Enclomiphene is right for them can schedule a consultation at MOPE Clinic with Chris Rue, FNP-C. About MOPE Clinic MOPE Clinic is a leading hormone optimization and wellness center dedicated to improving men’s and women’s health through personalized, research-backed care. Led by Chris Rue, FNP-C, the clinic specializes in testosterone optimization, peptide therapy, weight loss solutions, and integrative functional medicine. Chris Rue Metairie Optimal Performance Enhancement +1 504-265-5491 email us here Visit us on social media: LinkedIn Instagram Facebook Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.